Vera Therapeutics (VERA) Stock Forecast & Price Target

Compare

751 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VERA Analyst Ratings

Strong Buy

11 Buy

1 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Vera

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VERA Stock 12 Month Forecast

Average Price Target

$74.08

▲(44.63% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Vera Therapeutics in the last 3 months. The average price target is $74.08 with a high forecast of $100.00 and a low forecast of $33.00. The average price target represents a 44.63% change from the last price of $51.22.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","60":"$60","101":"$101","39.5":"$39.5","80.5":"$80.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,39.5,60,80.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,38.15384615384615,43.30769230769231,48.46153846153847,53.61538461538461,58.769230769230774,63.92307692307693,69.07692307692308,74.23076923076923,79.38461538461539,84.53846153846155,89.6923076923077,94.84615384615385,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,36.16,39.32,42.48,45.64,48.8,51.959999999999994,55.12,58.28,61.44,64.6,67.75999999999999,70.91999999999999,{"y":74.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33,33,33,33,33,33,33,33,33,33,33,33,33,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$74.08

Lowest Price Target$33.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Choi

Goldman Sachs

$55→$95

Buy

85.47%

Upside

Reiterated

12/19/25

Vera Therapeutics (VERA) Receives a Buy from Goldman Sachs

Dina Ramadane

Bank of America Securities

Not Ranked

Bank of America Securities

$48→$66

Buy

28.86%

Upside

Reiterated

12/19/25

Vera Therapeutics: Reinforced Buy on Atacicept’s Leading IgAN Profile, Robust Cash Runway, and Expanded Peak Sales Potential

Anupam Rama

J.P. Morgan

$99→$96

Buy

87.43%

Upside

Reiterated

12/18/25

Vera Therapeutics price target lowered to $96 from $99 at JPMorganVera Therapeutics price target lowered to $96 from $99 at JPMorgan

Gavin Clark-Gartner

Evercore ISI

$97→$95

Buy

85.47%

Upside

Reiterated

12/18/25

Evercore ISI Remains a Buy on Vera Therapeutics (VERA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$33

Hold

-35.57%

Downside

Reiterated

12/11/25

Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)

Ritu Baral

TD Cowen

$60→$73

Buy

42.52%

Upside

Reiterated

12/05/25

Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections

Rami Katkhuda

LifeSci Capital

$70

Buy

36.67%

Upside

Reiterated

12/03/25

Strategic Positioning and Market Opportunities Favor Vera Therapeutics: A Buy Recommendation

Arthur He CFA

H.C. Wainwright

$90

Buy

75.71%

Upside

Reiterated

11/26/25

Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept's Commercial Potential and Favorable Valuation

Mohit Bansal

Wells Fargo

$70

Buy

36.67%

Upside

Reiterated

11/26/25

Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)

Farzin Haque

Jefferies

$45

Buy

-12.14%

Downside

Reiterated

11/26/25

Vera Therapeutics (VERA) Gets a Buy from Jefferies

Dina Ramadane

Bank of America Securities

Not Ranked

Bank of America Securities

$48

Buy

-6.29%

Downside

Reiterated

11/25/25

Buy Recommendation for Vera Therapeutics: Atacicept's Market Potential and Efficacy Drive Positive Outlook

Vamil Divan

Guggenheim

$56

Buy

9.33%

Upside

Reiterated

11/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Genmab (NASDAQ: GMAB) and Vera Therapeutics (NASDAQ: VERA)

Pete Stavropoulos

Cantor Fitzgerald

$100

Buy

95.24%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

Andy Chen

Wolfe Research

Hold

―

Downgraded

08/04/25

Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchVera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Ryan Deschner

Raymond James

$73

Buy

42.52%

Upside

Reiterated

06/06/25

Vera Therapeutics (VERA) Receives a Buy from Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Choi

Goldman Sachs

$55→$95

Buy

85.47%

Upside

Reiterated

12/19/25

Vera Therapeutics (VERA) Receives a Buy from Goldman Sachs

Dina Ramadane

Bank of America Securities

Not Ranked

Bank of America Securities

$48→$66

Buy

28.86%

Upside

Reiterated

12/19/25

Vera Therapeutics: Reinforced Buy on Atacicept’s Leading IgAN Profile, Robust Cash Runway, and Expanded Peak Sales Potential

Anupam Rama

J.P. Morgan

$99→$96

Buy

87.43%

Upside

Reiterated

12/18/25

Vera Therapeutics price target lowered to $96 from $99 at JPMorganVera Therapeutics price target lowered to $96 from $99 at JPMorgan

Gavin Clark-Gartner

Evercore ISI

$97→$95

Buy

85.47%

Upside

Reiterated

12/18/25

Evercore ISI Remains a Buy on Vera Therapeutics (VERA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$33

Hold

-35.57%

Downside

Reiterated

12/11/25

Wedbush Keeps Their Hold Rating on Vera Therapeutics (VERA)

Ritu Baral

TD Cowen

$60→$73

Buy

42.52%

Upside

Reiterated

12/05/25

Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections

Rami Katkhuda

LifeSci Capital

$70

Buy

36.67%

Upside

Reiterated

12/03/25

Strategic Positioning and Market Opportunities Favor Vera Therapeutics: A Buy Recommendation

Arthur He CFA

H.C. Wainwright

$90

Buy

75.71%

Upside

Reiterated

11/26/25

Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept's Commercial Potential and Favorable Valuation

Mohit Bansal

Wells Fargo

$70

Buy

36.67%

Upside

Reiterated

11/26/25

Wells Fargo Keeps Their Buy Rating on Vera Therapeutics (VERA)

Farzin Haque

Jefferies

$45

Buy

-12.14%

Downside

Reiterated

11/26/25

Vera Therapeutics (VERA) Gets a Buy from Jefferies

Dina Ramadane

Bank of America Securities

Not Ranked

Bank of America Securities

$48

Buy

-6.29%

Downside

Reiterated

11/25/25

Buy Recommendation for Vera Therapeutics: Atacicept's Market Potential and Efficacy Drive Positive Outlook

Vamil Divan

Guggenheim

$56

Buy

9.33%

Upside

Reiterated

11/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), Genmab (NASDAQ: GMAB) and Vera Therapeutics (NASDAQ: VERA)

Pete Stavropoulos

Cantor Fitzgerald

$100

Buy

95.24%

Upside

Reiterated

11/06/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

Andy Chen

Wolfe Research

Hold

―

Downgraded

08/04/25

Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe ResearchVera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research

Ryan Deschner

Raymond James

$73

Buy

42.52%

Upside

Reiterated

06/06/25

Vera Therapeutics (VERA) Receives a Buy from Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vera Therapeutics

1 Month

xxx

Success Rate

15/24 ratings generated profit

Average Return

+9.41%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +9.41% per trade.

3 Months

xxx

Success Rate

13/21 ratings generated profit

Average Return

+39.58%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +39.58% per trade.

1 Year

Vamil DivanGuggenheim

Success Rate

6/8 ratings generated profit

Average Return

+61.27%

reiterated a buy rating last month

Copying Vamil Divan's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +61.27% per trade.

2 Years

xxx

Success Rate

21/21 ratings generated profit

Average Return

+88.67%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +88.67% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VERA has received 24 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VERA average Analyst price target in the past 3 months is 74.08.

Each month's total comprises the sum of three months' worth of ratings.

VERA Financial Forecast

VERA Earnings Forecast

Next quarter’s earnings estimate for VERA is -$1.29 with a range of -$1.62 to -$1.11. The previous quarter’s EPS was -$1.26. VERA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.

No data currently available

VERA Sales Forecast

Next quarter’s sales forecast for VERA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. VERA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VERA has Performed in-line its overall industry.

VERA Stock Forecast FAQ

What is VERA’s average 12-month price target, according to analysts?

Based on analyst ratings, Vera Therapeutics’s 12-month average price target is 74.08.

What is VERA’s upside potential, based on the analysts’ average price target?

Vera Therapeutics has 44.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VERA a Buy, Sell or Hold?

Vera Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.

What is Vera Therapeutics’s price target?

The average price target for Vera Therapeutics is 74.08. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $33.00. The average price target represents 44.63% Increase from the current price of $51.22.

What do analysts say about Vera Therapeutics?

Vera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of VERA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vera Therapeutics (VERA) Stock Forecast & Price Target

VERA Analyst Ratings

VERA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vera Therapeutics

VERA Analyst Recommendation Trends

VERA Financial Forecast

VERA Earnings Forecast

VERA Sales Forecast

VERA Stock Forecast FAQ

Detailed List of Analyst Forecasts